Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-03
2007-07-03
Tucker, Zachary C (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S235800, C514S256000, C514S400000, C544S139000, C544S333000, C544S370000, C548S338100
Reexamination Certificate
active
10771725
ABSTRACT:
The present invention is directed to imidazolyl derivatives or pharmaceutically acceptable salts thereof which are useful as agonists or antagonists of somatostatin receptors, having the following formula (I),wherein the substituents are defined in the specification.
REFERENCES:
patent: 5128355 (1992-07-01), Carini et al.
patent: 5733882 (1998-03-01), Carr et al.
patent: 6852725 (2005-02-01), Thurieau et al.
patent: 7026289 (2006-04-01), Cawthorne et al.
patent: 2004/0072734 (2004-04-01), Cawthorne et al.
patent: 0 253 310 (1994-10-01), None
patent: 2.132.632 (1972-11-01), None
patent: 218 460 (1987-09-01), None
patent: 94/04494 (1994-03-01), None
patent: WO 95/08550 (1995-03-01), None
patent: 96/11927 (1996-04-01), None
patent: 97/24119 (1997-07-01), None
patent: 97/30053 (1997-08-01), None
patent: 97/43278 (1997-11-01), None
patent: 97/45425 (1997-12-01), None
patent: 98/27108 (1998-06-01), None
patent: 99/64401 (1999-12-01), None
patent: 99/65942 (1999-12-01), None
patent: 00/00477 (2000-01-01), None
von Geldern et al, “Azole Endothelin Antagonists. 1. A Receptor Model Explains an Unusual Structure-Activity Profile” Journal Medicinal Chemistry, vol. 39(4), pp. 957-967 (1996).
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.” Archives of toxicology. Supplement. Archiv fur Toxikologie. supplement, vol. 7, pp. 219-231 (1984).
Hans Bundgaard, Design of Prodrugs, p. 1. © 1985 Elsevier Science Publishers.
Richard B. Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-400. © 1992 Academic Press, Inc.
Emery et al, “Anti-Secretory properties of non-peptide somatostatin receptor agonists in isolated rat colon: luminal activity and possible interaction with p-glycoprotein” British Journal of Pharmacology, vol. 135, pp. 1443-1448 (2002).
Gordon et al, “Synthetic Approaches to the “Azole” Peptide Mimetics” Tetrahedron Letters, vol. 34(12), pp. 1901-1904 (1993).
Robbins, R.J., J. Clin. Endocr. Metab., 82:15-17 (1997).
Flogstad A.K., et al., J. Clin. Endocr. Metab. 82:23-28 (1997).
Caron P., et al., J. Clin. Endocr. Metab. 82:18-22 (1997).
Grant, M.B., et al., Circulation, 89:1511-1517 (1994).
Fedorak, R.N., et al., Can. J. Gastroenterology, 3, No. 2, 53-57 (1989).
Soudah, H., et al., Gastroenterology, 98, No. 5, Part 2, Suppl., A129 (1990).
Hartley, J.E., et al., J. Roy. Soc. Med., 85, pp. 107-108 (1992).
Koberstein, B., et al., Z. Gastroenterology, 28, 295-301 (1990).
Christensen, C., Acta Chir. Scand. 155, 541-543 (1989).
Laron, Z., Israel J. Med. Sci., 26, No. 1, 1-2 (1990).
Wilson, D.C., Irish J. Med. Sci., 158, No. 1, 31-32 (1989).
Micic, D., et al., Digestion, 16, Suppl. 1.70. Abs. 193 (1990).
Bauer, W., Europ. J. Pharmacol., 183, 55 (1990).
Mozell, E., et al., Surg. Gynec. Obstet., 170, 476-484 (1990).
Cello, J.P., et al., Gastroenterology, 98, No. 5, Part 2, Suppl., A163 (1990).
Petrelli, N., et al., Proc. Amer. Soc. Clin. Oncol., vol. 10, P 138, Abstr. No. 417 (1991).
Soudah, H., et al., Clin. Res., vol. 39, p. 303A (1991).
O'Donnell, L.J.D., et al., Aliment. Pharmacol. Therap., vol. 4., 177-181 (1990).
Tulassay, Z., et al., Gastroenterology, 98, No. 5, Part 2, Suppl., A238 (1990).
Nott, D.M., et al., Brit. J. Surg., vol. 77, p. A691 (1990).
Branch, M.S., et al., Gastroenterology, vol. 100, No. 5, Part 2 Suppl., p. A425 (1991).
Hasler, W., et al., Gastroenterology, vol. 100, No. 5, Part 2, Suppl., p. A448 (1991).
Clark, R.V., et al., Clin. Res. 38, p. 943A (1990).
Ambrosi B., et al., Acta Endocr. (Copenh.) 122, 569-576 (1990).
Miller, D., et al., Canad. Med. Ass. J., vol. 145, pp. 227-228 (1991).
Chang, T.C., et al., Brit. Med. J., 304, p. 158 (1992).
Chan, A.W., et al., Horm. Res., 36:86-87 (1991).
Palmieri, G.M.A., et al., J. of Bone and Mineral Research, 7, (Suppl. 1), p. S240 (Abs. 591) (1992).
Prelevic, G.M., et al., Metabolism Clinical and Experimental, 41, Suppl. 2, pp. 76-79 (1992).
Weckbecker, G., et al., Pharmac. Ther., 60:245-264 (1993).
Bartlett, D.L., et al., Surg. Forum., 42, pp. 14-16 (1991).
Hoeldtke, R.D., et al., Arch. Phys. Med. Rehabil., 69, 895-898 (1988).
Kooner, J.S., et al., Brit. J. Clin. Pharmacol., 28, 735P-736P (1989).
Hoeldtke, R.D., et al., Am. J. Med., 81:83-87 (1986).
Abelson, J.L., et al., Clin. Psychopharmacol., 10, 128-132 (1990).
Malarkey, W.B., et al., Neuroendocrinology, 49:267-274 (1989).
Dimitriadis, G., et al., Metabolism, 32:987-992 (1983).
Orskov, L., et al., Metabolism, 45:211-217 (1996).
McCombe, M., et al., Eye, 5:569-575 (1991).
Campbell, P.J., et al., Metabolism, 37:34-37 (1988).
Flyvbjerg, A., et al., Kidney Int., 41:805-812 (1992).
Kayasseh L, Lancet, 1:844-846 (1980).
Nubiola, P., et al., Ann. Surg., 210:56-58 (1989): Erratum in Ann. Surg., 211:246, (1990).
Anand, B.S., et al., Am. J. Gastroenterol., 89:267-270 (1994).
Hopman, W.P., et al., Ann. Surg., 207:155-159 (1988).
Eriksson, B., et al., Scand. J. Gastroenterol., 23:508-512 (1988).
Buchler, M.W., et al., Gut, 35:S15-S19 (1994).
Souquet, J.C., et al., Cancer, 59:1654-1660 (1987).
Danesi, R., et al., Clin. Cancer Res., 3:265-72 (1997).
Mantyh, P.W., et al., Peptides, 10:627-645 (1989).
Hayry, P., et al., FASEB J. 7:1055-1060 (1993.
Yumi, K., et al., Lab. Invest., 76:329-338 (1997).
Rossini, F.P., et al., Am. J. Gastroenterol., 88:1424-1427 (1993).
Ladas, S.D., et al., Hepatogastroenterology, 45:761-4 (1998.
Albert, Rainer, et al.; “Direct Synthesis of [DOTA-Dphe1]-Octreotide (SMT487) : . . . ”; Bioorganic & Medicinal Chemistry Letters, 1998,vol. 8; pp. 1207-1210; XP002124712.
Gramberg, Dieter et al; “Synthesis of a Type Vibeta-Turn Peptide . . . ”;Helvetica Chimica Acta; 1995, vol. 78, pp. 1588-1606; XP000612160.
Hirschmann, Ralph et al.; “De Novo Design and Synthesis of Somatostatin . . . ”; Journal of the American Chemical Society; 1996, vol. 115, No. 26; pp. 12550-12568; XP002124710.
Hirschmann, Ralph et al.; “Nonpeptidal Peptidomimetics with a beta-D-glucose Scaffolding”; Journal of the American Chemical Society; 1992, vol. 114, No. 23; XP002124711.
Papageorgiou, Christos et al.; “A Non-peptide ligand for the Somatostatin Receptor having a Benzodiazepinone Structure”; Bioorganic & Medicinal Chemistry Letters; 1996, vol. 6, No. 3; pp. 267-272; XP004135075.
Ellinger and Goldberg; J. Chem. Soc.; 1949; 263, 266; Beilstein Registry No. 1965.
Ellinger and Goldberg; J. Chem. Soc.; 1949; 263, 266; Beilstein Registry No. 3689018.
Ellinger and Goldberg; J. Chem. Soc.; 1949; 263, 266; Beilstein Registry No. 3798855.
Bornowski, Heinz et al.; Chem. Abstract 1973, 78:136289.
Gordon, Thomas D. et al.; Chem. Abstract 1997, 127:248417.
Stocker, Fred B. et al.; Chem. Abstract, 1970, 72:121434.
Towliati, Hossein; Chem. Abstract, 1971, 74:53642.
Von Geldern, Thomas W. et al.; Chem Abstract, 1996, 124:193276.
Von Geldern, Thomas W. et al.; Chem. Abstract, 1996, 124:127005.
Von Geldern, Thomas W. et al.; Chem. Abstract, 1996, 124:164291.
Galcera Marie-Odile
Gordon Thomas D.
Moinet Christophe Philippe
Morgan Barry A.
Poitout Lydie Francine
Feeney Alan F.
Fish & Richardson
Societe de Conseils de Recherches et d'Applications Scientifique
Tucker Zachary C
Uhm Tony K.
LandOfFree
Imidazolyl derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazolyl derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazolyl derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3768195